Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification

Douglas G. Ward, Naheema S. Gordon, Rebecca H. Boucher, Sarah J. Pirrie, Laura Baxter, Sascha Ott, Lee Silcock, Celina M. Whalley, Joanne D. Stockton, Andrew D. Beggs, Mike Griffiths, Ben Abbotts, Hanieh Ijakipour, Fathimath N. Latheef, Robert A. Robinson, Andrew J. White, Nicholas D. James, Maurice P. Zeegers, K. K. Cheng, Richard T. Bryan*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)532-544
Number of pages13
JournalBJU International
Volume124
Issue number3
DOIs
Publication statusPublished - Sep 2019

Keywords

  • mutations
  • diagnosis
  • prognosis
  • detection
  • urine
  • DNA
  • #BladderCancer
  • #blcsm
  • TERT PROMOTER MUTATIONS
  • LIQUID BIOPSIES
  • RECURRENCE
  • BIOMARKERS
  • CARCINOMA
  • GUIDELINES

Cite this

Ward, D. G., Gordon, N. S., Boucher, R. H., Pirrie, S. J., Baxter, L., Ott, S., Silcock, L., Whalley, C. M., Stockton, J. D., Beggs, A. D., Griffiths, M., Abbotts, B., Ijakipour, H., Latheef, F. N., Robinson, R. A., White, A. J., James, N. D., Zeegers, M. P., Cheng, K. K., & Bryan, R. T. (2019). Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification. BJU International, 124(3), 532-544. https://doi.org/10.1111/bju.14808